CD8A and neoplasm: TIM-3 and PD-1 blockade has been shown to improve the survival of tumor-bearing mouse by boosting the antigen presentation of classical type 2 dendritic cells (imcDC2) and improving the tumor-killing function of CD8+ tissue-resident memory cells CD8+ T cells (CD8+TRMs) [238].